Introduction
Apolipoprotein AI-mediated cholesterol efflux is a key step in reverse cholesterol transport -a concept first formulated by Glomset more than 30 years ago [1, 2] . According to this model, excess cholesterol is removed from peripheral tissues by the action of apolipoprotein AI and esterified by lecithin:cholesterol acyltransferase. The resulting cholesterol esters are transported back to the liver for bile secretion, either directly in the form of high-density lipoproteins (HDLs) or after transfer to apolipoprotein B-containing lipoproteins by the action of cholesterol ester transfer protein. The model proposes that the cholesterol and lipids used for the formation and maturation of HDL derive both from non-hepatic peripheral cells and from the metabolism and remodeling of triglyceride-rich, apolipoprotein B-containing lipoproteins, and suggests that high levels of HDL cholesterol reflect a greater degree of cholesterol efflux and thus more efficient reverse cholesterol transport.
Recent results have concentrated many research groups on the study of a new candidate participant in this process -the ATP-binding cassette (ABC) transporter ABCA1. Defects in ABCA1 cause Tangier disease [3] [4] [5] a condition characterized by reduced levels of plasma HDL cholesterol, decreased apolipoprotein AI-mediated cholesterol efflux from cells, sterol accumulation in tissue macrophages, and a possible increase in atherosclerotic risk.
The characteristics and molecular basis of Tangier disease fit with the notion that low levels of HDL cholesterol generally reflect inefficient cholesterol efflux.
ABCA1 is expressed by macrophages and promotes apolipoprotein AI-mediated cholesterol efflux in healthy individuals. HDL formation occurs at the ABCA1-expressing sites in order to allow transport of excess cholesterol back to the liver and the lack of ABCA1 reduces apolipoprotein AI-mediated cholesterol efflux from peripheral cells as well as circulating levels of apolipoprotein AI and HDL cholesterol. The absence of effective apolipoprotein AI-mediated cholesterol efflux in Tangier disease also promotes cholesterol accumulation in peripheral (macrophage-rich) tissues, and, as a consequence, enhanced formation of lipid plaques. Lack of plasma HDL also reduces low-density cholesterol (LDL) in the plasma, probably because of an inability of cholesterol ester transfer protein to transfer cholesterol esters from HDL to LDL.
The classic concept of reverse cholesterol transport implies that macrophages or other non-hepatic peripheral cells contribute most, if not all, of the cholesterol in plasma HDL, so that reduced efflux from the periphery leads to low circulating HDL cholesterol. However, recent studies indicated that this may not be the case. Selective inactivation of ABCA1 in macrophages of apolipoprotein E-deficient mice markedly increased atherosclerosis and foam cell formation without altering the plasma lipids and HDL cholesterol levels, whereas complete absence of ABCA1 in apolipoprotein E or LDL receptor-deficient mice was accompanied by reduced plasma cholesterol and severe skin xanthomas characterized by marked foamy macrophages and cholesterol ester accumulation, but did not affect development, progression, or composition of atherosclerotic lesions [6] . Moreover, selective expression of ABCA1 in the macrophages of ABCA1-deficient mice resulted in only a small increase in levels of apolipoprotein AI and HDL cholesterol [7] .
To study the contribution of ABCA1 on plasma lipid profiles and atherosclerosis, three independent groups recently created four different lines of ABCA1-overexpressing mice [8] [9] [10] . As nicely reviewed by Joyce et al. [11 . ], analyses of these mice do not confirm the idea that enhanced ABCA1 expression in general increases HDL cholesterol levels in vivo. Despite different genetic backgrounds of the mouse strains, different promoters controlling ABCA1 expression and different sources and types of the human transgene used for generating the transgenic animals, cholesterol efflux from isolated macrophages was increased in all three studies. However, only in the studies presented by Singaraja et al. and Vaisman et al. were plasma lipid profiles altered [9,10], being unaltered in the ABCA1-overexpressing mouse model used by Cavelier et al. [8] .
A possible explanation for these apparently contradictory findings may be the central role of the liver in HDL formation. The liver is a major site of apolipoprotein AI and ABCA1 expression, contributing significantly to the plasma pool of nascent HDL [8, 9, [12] [13] [14] 15 . , 16, 17] . Moreover, selective hepatic overexpression of ABCA1 increased plasma HDL cholesterol [8, 18 . ], while ABCA1 expressed by macrophages has only a slight effect on plasma HDL levels [6, 7] . Finally, enhanced expression of ABCA1 in mouse liver by means of an adenovirus vector increased apolipoprotein AI-dependent cholesterol efflux in primary hepatocytes and raised levels of total cholesterol, phospholipids, free cholesterol, HDL cholesterol, apolipoprotein E, and apolipoprotein AI in the whole animal [19 . ]. Thus, one explanation for the variation in the results reviewed by Joyce et al. ] compared with the expression of the endogenous mouse ABCA1 gene in the model used by Cavelier et al. [8] . This low level of expression of the transgene is probably responsible for the lack of change in the plasma lipid profiles.
A further interesting report investigated the retrovirusmediated overexpression of apolipoprotein AI in apolipoprotein E-deficient bone marrow cells that were transplanted into apolipoprotein E-deficient mice with preexisting atherosclerosis [20 . ]. This procedure resulted in a reduction in the atherosclerotic lesions in the proximal aorta. Furthermore, apolipoprotein AI-expressing peritoneal macrophages isolated from the apolipoprotein E-deficient mice that had been reconstituted with apolipoprotein AI-overexpressing marrow showed increased expression of both ABCA1 and ABCG1. The authors speculate that the upregulation of these ABC transporters may be the main source of the antiatherogenic effect of apolipoprotein AI overexpression, although they were at a loss to explain the underlying mechanism.
Although the importance of ABCA1 expression for the regulation of the plasma HDL cholesterol level and the development of atherosclerosis has been shown in mice [8] [9] [10] 21] , findings in humans cast doubt on the clinical importance of ABCA1 in this respect. In a genetic study in Finns, a genetically homogeneous population with a high prevalence of coronary heart disease, for example, Kakko et al. [22 . ] found the ABCA1 locus to be of minor importance in regulating HDL cholesterol levels. A recent study in Dutch subjects with familial hypo-alipoproteinemia, but without mutations in ABCA1, found no correlation between cholesterol efflux and apolipoprotein AI or HDL cholesterol levels [23] . A caveat must be entered in this regard, however, because other studies have shown that sequence variances in ABCA1 may affect plasma lipids or the development or progression of atherosclerosis in certain populations [24] [25] [26] .
Thus, current results indicate that ABCA1 plays a key role in hepatic cholesterol efflux, inducing pathways that modulate cholesterol homeostasis in the liver, and seem to establish the liver as a more important source of plasma HDL cholesterol than peripheral cells such as macrophages. On the other hand, increased expression of ABCA1, apolipoprotein AI, and apolipoprotein E in macrophages has been clearly shown to protect against atherosclerosis. Thus, the concept that low levels of HDL cholesterol reflect inefficient reverse cholesterol transport may be too simple. The physiological role of HDL is more complex than previously thought, and the direct effect of high HDL cholesterol levels on progression of atherosclerosis is unclear. Therefore, more specific studies and better well-defined animal models are required to understand the complexity of the reverse cholesterol transport process and to demonstrate the importance of ABCA1 as a drug target. The concentration of plasma HDL cholesterol has been found to be a negative predictor of premature coronary heart disease and there is experimental evidence that HDL protects against the development of atherosclerosis. However, there remain many unanswered questions that must be answered before HDL cholesterol-raising therapies are embarked on as a strategy to prevent coronary heart disease. This review highlights what is currently unknown in the story of HDL. locus is not a major determinant of HDL-C levels in a population at high risk for coronary heart disease. Atherosclerosis 2003; 166:285-290. This study presents interesting findings that ABCA1 is not a major determinant for regulation of HDL cholesterol plasma levels in a homogenous Finnish population. Although, a broader study in this respect including different and larger populations is necessary to show the importance of variations in ABCA1 for risk of coronary heart disease. This is a nice report about recent findings on surprising uses for the noncoding junk DNA in eukaryotic genomes: (1) introns going on to build proteins of their own despite being cut out of the pre-messenger RNA; such intron-encoded enzymes can, for example, inject new stretches of DNA into precise defined spots in a genome; (2) inteins, peptide pieces of a proteins, that are immediately and spontaneously spliced out of the proteins during protein folding; inteins can, for example, reassemble proteins or link proteins to small molecules. 
